Skip to main content
Caplight Logo









Nectero Therapeutics

Nectero Therapeutics

Private
Tempe, ArizonaHealthcare & Life Scienceshttps://necterotherapeutics.com/

Last Round

Series D

Apr 11, 2024

Est. Valuation

$170M

Total Funding Raised

$211.5M

Company Overview

Nectero Therapeutics is a clinical-stage biotechnology company developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

abdominal aortic aneurysmAAAendovascular treatmentvascular surgeryminimally invasive surgerymedical devicepentagalloyl glucosePGGbiotechaneurysm repairendovascular devicevascular healthclinical-stage biotechinterventional cardiology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nectero Therapeutics Comparables

Compare Nectero Therapeutics with similar companies based on industry and business-model similarity.

Nectero Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shape Memory Medical
75%
Taurus Vascular
73%
W. L. Gore & Associates
73%

Nectero Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DApr 11, 2024
Series DJan 18, 2024
Series CSep 10, 2021
Series BApr 30, 2020

Nectero Therapeutics Investors

Notable investors and investment history

Nectero Therapeutics investors
InvestorRounds
Aphelion CapitalSeries D
Cadence MedTech VenturesSeries D
Cadence Healthcare VenturesSeries D
Norwest Venture PartnersSeries D
Boston Scientific CorporationSeries D, Series C
BioStar CapitalSeries D

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 10, 2021

    $20M round led by Boston Scientific Corporation and Cortex, Inc.

Nectero Therapeutics Filings

Explore SEC and related filing metadata, where available.

Nectero Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nectero Therapeutics's valuation, stock price, and market status.

Is Nectero Medical a public or private company?

Nectero Medical is a private company.

What is the current stock price of Nectero Medical?

Nectero Medical is a private company with no public stock price. No recent secondary market data is available.

How much is Nectero Medical worth (valuation)?

Valuation information for Nectero Medical is not publicly available.

Can I buy Nectero Medical stock?

Nectero Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Nectero Medical's last funding round?

Nectero Medical's most recent funding round was Series D on April 11, 2024.

Who are the main investors in Nectero Medical?

Key investors in Nectero Medical include Norwest Venture Partners, Boston Scientific Corporation, Boston Scientific Ventures.

Will Nectero Medical IPO soon?

No public IPO plans have been announced for Nectero Medical.

How can I track Nectero Medical secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nectero Medical's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTempe, Arizona
Employee Range24
Year Founded2017
Last FundingApr 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?